Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) (2020 - 2025)

KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.99 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 6.6% year-over-year to -$0.99; the TTM value through Apr 2025 reached -$3.83, down 11.34%, while the annual FY2025 figure was -$3.69, 7.27% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2025 was -$0.99 at KalVista Pharmaceuticals, down from -$0.91 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.74 in Q3 2023 and bottomed at -$1.06 in Q2 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.87 (2024), against an average of -$0.89.
  • The largest annual shift saw EPS (Weighted Average and Diluted) decreased 17.57% in 2024 before it increased 6.6% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.8 in 2023, then dropped by 13.75% to -$0.91 in 2024, then fell by 8.79% to -$0.99 in 2025.
  • Per Business Quant, the three most recent readings for KALV's EPS (Weighted Average and Diluted) are -$0.99 (Q2 2025), -$0.91 (Q4 2024), and -$0.87 (Q3 2024).